eligibility_summary
Adults (≥18) with relapsed/refractory multiple myeloma, consented, ≥3 prior therapies, refractory to ≥1 proteasome inhibitor, ≥1 IMiD, and an anti-CD38 mAb, with IMWG-defined progression on last therapy, and starting teclistamab as routine care or started ≤14 days before screening. Exclude if previously in a teclistamab trial/SPR or if teclistamab began >14 days before screening.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Teclistamab (Tecvayli), an anti-BCMA×CD3 bispecific IgG4 monoclonal antibody T‑cell engager. Mechanism: binds BCMA (TNFRSF17) on multiple myeloma plasma cells and CD3 on endogenous T cells, forming an immune synapse that activates TCR/CD3 signaling, drives T‑cell proliferation and cytotoxic effector release (perforin/granzymes, cytokines), and selectively lyses BCMA+ myeloma cells. Targets: BCMA-expressing malignant plasma cells, engages CD3+ T cells, key pathways include BCMA-directed tumor antigen recognition and T‑cell activation/cytotoxicity. Study: prospective observational, real-world use in Belgian relapsed/refractory MM after ≥3 prior lines.